Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.43 |
| ▸ | CA2 | P00918 | 9/20 | 0.43 |
| ▸ | CA9 | Q16790 | 8/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | CA3 | P07451 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11779434 | 0.98 | CA1 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL8744436 | 0.98 | CA1 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL11238583 | 0.98 | CA1 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL2417827 | 0.98 | CA1 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL31371864 | 0.98 | CA1 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL7545491 | 0.98 | CA1 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL3140135 | 0.98 | CA1 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL2230465 | 0.98 | CA1 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL11423565 | 0.97 | CA1 (0.43) | CA1CA2CA9CA12CA7 | |
| SCHEMBL11697143 | 0.97 | CA1 (0.43) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586599-B1 | Formating carbon-carbon bonds between carbocyclic halogen and organosilicon compounds in the presence of coordination catalysts, nitrogen compounds and bases; efficiency; catalysis | UNIVERSITY OF NEW ORLEANS RESEARCH AND TECHNOLOGY FOUNDATION | 2003-07-01 | — | — | US | claimed |
| US-6403801-B1 | MIXING IN LIQUID MEDIUM STRONG BASE, ARYL HALIDE OR ARYL PSEUDOHALIDE, ARYLBORONIC ACID, NICKEL, PALLADIUM OR PLATINUM COMPOUND, N-HETEROCYCLIC CARBENE SELECTED FROM IMIDAZOLINE-2-YLIDENE, BIS(IMIDAZOLINE-2-YLIDENE) OR SALTS | UNIVERSITY OF NEW ORLEANS RESEARCH & TECHNOLOGY FOUNDATION | 2002-06-11 | — | — | US | claimed |
| US-6403802-B1 | MIXING IN LIQUID MEDIUM STRONG BASE, ARYL HALIDE OR ARYL PSEUDOHALIDE, PRIMARY AND/OR SECONDARY AMINE, NICKEL, PALLADIUM OR PLATINUM COMPOUND, N-HETEROCYCLIC CARBENE SUCH AS IMIDAZOLINE-2-YLIDENE, BIS(IMIDAZOLINE-2-YLIDENE) OR SALTS | UNIVERSITY OF NEW ORLEANS RESEARCH & TECHNOLOGY FOUNDATION | 2002-06-11 | — | — | US | claimed |
| US-6369265-B1 | HETEROCOUPLING REACTION, MIXING IN A LIQUID AN ARYL HALIDE, BONDING TO AROMATIC RINGS, GRIGNARD REACTION, METAL COMPOUND AND HETEROCYCLIC CARBENE | UNIVERSITY OF NEW ORLEANS RESEARCH & TECHNOLOGY FOUNDATION | 2002-04-09 | — | — | US | claimed |
| US-6362357-B1 | PHOSPHINE; USING ARYL HALIDES; ORGANOTIN COMPOUNDS | UNIVERSITY OF NEW ORLEANS RESEARCH & TECHNOLOGY FOUNDATION | 2002-03-26 | — | — | US | claimed |
| WO-2001066248-A2 | C-C AND C-N COUPLING CATALYST COMPRISING TRANSITION METAL AND CARBENE | UNIVERSITY OF NEW ORLEANS RESEARCH AND TECHNOLOGY FOUNDATION (US) | 2001-09-13 | — | — | WO | claimed |
| US-5602228-A | Nickel phosphate catalysts | MAXDEM INCORPORATED (US) | 1997-02-11 | — | — | US | claimed |
| WO-1996039455-A1 | NICKEL PHOSPHITE CATALYSTS | MAXDEM INCORPORATED (US) | 1996-12-12 | — | — | WO | claimed |
| CN-109422674-B | Organic molecules, in particular for optoelectronic devices | 三星显示有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20240075151-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2024-03-07 | — | — | US | disclosed |
| US-20230406877-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KR) | 2023-12-21 | — | — | US | disclosed |
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | INTOCELL, INC. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-11773219-B2 | Functionalized polymers | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-20230285574-A1 | CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2023-09-14 | — | — | US | disclosed |
| EP-0985662-A2 | Linker binding carriers for organic synthesis, their production and use | Takeda Chemical Industries, Ltd. (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-5858907-A | Nickel phosphite catalysts | MAXDEM, INCORPORATED (US) | 1999-01-12 | — | — | US | disclosed |
| CN-1201393-A | Compositions and methods for treating bone deficiency disorders | ZYMOGENETICS INC (US) | 1998-12-09 | — | — | CN | disclosed |
| US-5602228-A | Nickel phosphate catalysts | MAXDEM INCORPORATED (US) | 1997-02-11 | — | — | US | disclosed |
| WO-1996039455-A1 | NICKEL PHOSPHITE CATALYSTS | MAXDEM INCORPORATED (US) | 1996-12-12 | — | — | WO | disclosed |
| US-4352788-A | ARTERIES | BRACCO INDUSTRIA CHIMICA S.P.A. (IT) | 1982-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285574-A1 | CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS | CD44, EPCAM, ALG1 | CA1 860/4885CA2 3633/4885CA9 1092/4885 |
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | GABRB3, GABRB2, GABRB1 | CA1 2795/4885CA2 3908/4885CA9 4784/4885 |
| US-11773219-B2 | Functionalized polymers | PARG, PUF60, PCBP1 | CA1 1988/4885CA2 4277/4885CA9 3071/4885 |
| US-20230406877-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | VIP, ANTXR2, TNFRSF9 | CA1 101/4885CA2 225/4885CA9 247/4885 |
| US-20240075151-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | TNF, TNFRSF1A, TNFSF11 | CA1 1032/4885CA2 4015/4885CA9 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.